Palbociclib
Brand name: Ibrance
Rank #23 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$755.1M
Total Cost
48,329
Total Claims
$755.1M
Total Cost
1,812
Prescribers
$16K
Cost per Claim
692
Beneficiaries
48,469
30-Day Fills
$417K
Avg Cost/Provider
27
Avg Claims/Provider
Share of Medicare Part D Spending
0.27%
of total Medicare Part D spending
$755.1M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $755.1M total
🔎 Data Overview
Ranked #23 out of 500 drugs tracked by total cost. Palbociclib represents a significant portion of Medicare drug spending.
At $15,624 per prescription, this is a high-cost medication. Expensive drugs drive Medicare spending growth and create access challenges for patients with coverage gaps.
Average cost of $416,727 per prescriber suggests this drug may be concentrated among specialists. High per-provider spending can sometimes indicate inappropriate prescribing or overly aggressive use.
Average cost of $1,091,199 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Palbociclib
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Luis Baez Vallecillo | Hematology-Oncology | San Juan, PR | 215 | $3.3M |
| 2 | Amy Vander Woude | Hematology-Oncology | Grand Rapids, MI | 185 | $2.8M |
| 3 | Wajeeha Razaq | Hematology-Oncology | Oklahoma City, OK | 160 | $2.5M |
| 4 | Christina Bi | Pharmacist | Roseville, CA | 173 | $2.4M |
| 5 | Nguyet Le-Lindqwister | Hematology-Oncology | Peoria, IL | 152 | $2.4M |
| 6 | Mark Romer | Hematology-Oncology | Dayton, OH | 143 | $2.3M |
| 7 | Matthew Tipping | Hematology-Oncology | Portland, OR | 159 | $2.2M |
| 8 | Punprapai Boriboonsomsin | Hematology-Oncology | Sylmar, CA | 148 | $2.1M |
| 9 | Maria Tirona | Medical Oncology | Huntington, WV | 129 | $2.0M |
| 10 | Chirag Shah | Hematology-Oncology | Toms River, NJ | 125 | $2.0M |
| 11 | Gurinderjit Kaur Sidhu | Hematology-Oncology | Stockbridge, GA | 125 | $2.0M |
| 12 | Hikaru Nakajima | Medical Oncology | East Stroudsburg, PA | 132 | $2.0M |
| 13 | Ramya Varadarajan | Hematology-Oncology | Newark, DE | 113 | $1.9M |
| 14 | Lindsey Prochaska | Hematology-Oncology | Wilmington, NC | 118 | $1.9M |
| 15 | Mala Reddy | Medical Oncology | Oakland, CA | 129 | $1.8M |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 20 | Paliperidone Palmitate (Invega Sustenna) | $832.3M | 252,388 |
| 21 | Insulin Aspart (Novolog Flexpen) | $831.6M | 958,823 |
| 22 | Budesonide/Formoterol Fumarate (Symbicort) | $759.4M | 1,452,561 |
| 23 | Palbociclib (Ibrance) | $755.1M | 48,329 |
| 24 | Nintedanib Esylate (Ofev) | $703.7M | 53,928 |
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology